Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Yusuke Tanigawara"'
Autor:
Kenro Hirata, Kayo Yoshida, Chikatoshi Katada, Akinori Watanabe, Takahiro Tsushima, Toshifumi Yamaguchi, Sachiko Yamamoto, Hideki Ishikawa, Yasunori Sato, Chiyo K. Imamura, Yusuke Tanigawara, Yoshinori Ito, Ken Kato, Yuko Kitagawa, Yasuo Hamamoto
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background In older patients, esophageal squamous cell carcinoma (ESCC) is difficult to treat using standard therapies, including surgery and cisplatin-based chemoradiotherapy. Paclitaxel (PTX) has radiosensitizing activity. We conducted a p
Externí odkaz:
https://doaj.org/article/09b052b87e8a4618ae3372b67d5b1297
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 44-54 (2022)
Abstract The identification of influenza epidemics and assessment of the efficacy of vaccination against this infection are major challenges for the implementation of effective public health strategies, such as vaccination programs. In this study, we
Externí odkaz:
https://doaj.org/article/892b4a17d6c24d13be0764611e265de6
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 188-198 (2021)
Abstract Lenvatinib is a tyrosine kinase inhibitor of the vascular endothelial growth factor receptor used against nonoperative thyroid cancer; however, hypertension is a major dose‐limiting side effect. In this study, hypertension caused by lenvat
Externí odkaz:
https://doaj.org/article/85c1231cc5ff4549968c7727fb574bb3
Autor:
Toshimichi Nakamura, Kota Toshimoto, Wooin Lee, Chiyo K. Imamura, Yusuke Tanigawara, Yuichi Sugiyama
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 7, Iss 7, Pp 474-482 (2018)
The Tamoxifen Response by CYP2D6 Genotype‐based Treatment‐1 (TARGET‐1) study (n = 180) was conducted from 2012–2017 in Japan to determine the efficacy of tamoxifen dosing guided by cytochrome P450 2D6 (CYP2D6) genotypes. To predict its outcom
Externí odkaz:
https://doaj.org/article/d321e969e1c84baea31b14f8378e3959
Autor:
Hidefumi, Kasai, Kim Linda, Poppenberg, Valentina, Fermanelli, Yuki, Otani, Yusuke, Tanigawara
Publikováno v:
Therapeutic Drug Monitoring. 45:318-326
Neutropenia is a major dose-limiting toxicity of cancer chemotherapy. Semi-mechanistic mathematical models have been applied to describe the time course of neutrophil counts. The objectives of this study were to develop a mathematical model describin
Autor:
Eisuke Booka, Chiyo K. Imamura, Masashi Takeuchi, Hirofumi Kawakubo, Hiroya Takeuchi, Yusuke Tanigawara, Yuko Kitagawa, Narikazu Boku
Publikováno v:
Gastric Cancer. 25:770-782
The aim of this study was to evaluate clinical validity of the S-1 dosage formula based on body surface area (BSA) and creatinine clearance (CLcr) to achieve the target area under the concentration-time curve of 5-FU, which we had developed and refin
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 44-54 (2022)
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 44-54 (2022)
The identification of influenza epidemics and assessment of the efficacy of vaccination against this infection are major challenges for the implementation of effective public health strategies, such as vaccination programs. In this study, we develope
Publikováno v:
Blood. 140:4310-4311
Autor:
Yu Aoki, Hirofumi Kawakubo, Narikazu Boku, Masashi Takeuchi, Kazushige Wakuda, Yusuke Tanigawara, Taro Funakoshi, Minoru Kitago, Takuro Mizukami, Hiroya Takeuchi, Chiyo K. Imamura, Yasuo Hamamoto, Yuko Kitagawa, Takeshi Kawakami, Eisuke Booka
Publikováno v:
Cancer Science
In patients with impaired renal function, S‐1–related toxicities increase due to higher exposure of 5‐fluorouracil (5‐FU). Our previous pharmacokinetic study in 16 cancer patients with various renal functions developed an S‐1 dosage formula
Publikováno v:
Journal of Clinical Pharmacology
The prevention of fractures is the ultimate goal of osteoporosis treatments. To achieve this objective, developing a method to predict fracture risk in the early stage of osteoporosis treatment would be clinically useful. This study aimed to develop